National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
211
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

TABLE D-5.1 Morbidity and Mortality due to Acute Hepatitis B

Region

Population at Risk (millions)

Annual Incidence Rate (per 100,000)

Number of Cases

Deathsa

High Risk Regions

 

 

 

 

South and east Asia

1,516

68b

1,030,880

1,546

Sub-Saharan Africa

407

68b

276,760

415

Oceania

5

68b

3,400

5

Moderate Risk Regions

 

 

 

 

Central Asia

1,146

60c

687,600

1,031

North Africa

124

60c

74,400

112

South America

397

40d

158,800

238

Total

 

 

2,231,840

3,347,

aAssuming a case fatality rate of 1.5 per 1,000 cases.

bIncidence rate in China assumed applicable to all high-risk regions.

cAssumed to be close to Israel’s rate of 50 to 80 per 100,000.

dAssumed to be between rates in Israel and the United States.

SOURCE: Francis, personal communication, 1985.

Cases and deaths were divided proportionally by population size into the 5 to 14 and 15 to 59 years age groups. It was assumed that all cases in the under 5 years age group are asymptomatic, and that the number of cases in people 60 years of age and over is insignificant.

Cases were distributed into the acute categories as follows: 5 to 14 years age group, 25 percent in category A, 50 percent in category B, and 25 percent in category C; 15 to 59 years age group, 25 percent in category A, 25 percent in category B, and 50 percent in category C. An additional 3 percent of cases in each age group were assigned to category E, representing cases of chronic acute hepatitis (Berlin, 1980). Table D-5.2 shows the disease burden resulting from acute hepatitis B.

Primary Hepatocellular Carcinoma

PHC may occur in chronic hepatitis B carriers 20 years or more after an acute infection. The average survival rate of PHC is 6 months, so the numbers of cases and deaths are equal. The incidence rates in different populations are shown in Table D-5.3. Because of the time lag between acute hepatitis infection and PHC onset, it was assumed that the disease affects only two age groups. Cases and deaths were distributed proportionally according to the size of the population in each age group, and all cases were assigned to category E. Table D-5.4 shows the disease burden estimates for PHC.

Page
211
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)